Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ribon raises $65mm in Series B round

Executive Summary

Ribon Therapeutics Inc. (developing cancer therapies targeting cellular stress pathways) raised $65mm through its Series B round. Novartis Venture Fund led and was joined by new investors JJDC and Celgene, along with returning backers The Column Group, Deerfield Management, US Venture Partners, Osage University Partners, Takeda Ventures, and Euclidean Capital. The company will use the funds to advance its pipeline of small-molecule PARP inhibitors, including a lead PARP7 inhibitor being studied for squamous cell carcinoma of the lung.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies